QRX003 not checked

Quoin Pharmaceuticals

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2/3 trial completes
Trials
4 active
4 in total

What this is

How it works
How it works isn't classified yet
How it’s given
“QRX003Topical Lotion containing 2% active drug (serine protease inhibitor)”In the company’s words, NCT05521438 on ClinicalTrials.gov
Tested for
Netherton Syndrome (4 trials)
Main trialPhase 2/3
“This study has been designed to determine the safety, tolerability and efficacy of QRX003 lotion 2%, 4% QAM or 4% BID in subjects with Netherton Syndrome (NS) in comparison to vehicle”In the company’s words, NCT05521438 on ClinicalTrials.gov

Other drugs for Netherton Syndrome

All 2 drugs for Netherton Syndrome

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 2/3Active, not recruiting 30 Dec 2025 Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
Phase 2/3Recruiting 30 Dec 2026 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
Phase 2/3Recruiting 30 Dec 2026 Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
Phase 2/3Recruiting 31 Jan 2027 Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow QRX003

Following is part of Solo: you see every change to QRX003 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in